AGAli Ghorbani

Ali Ghorbani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ali Ghorbani has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of Patients with End-Stage Renal Disease Hospitalized with COVID-19 in Ahvaz Razi Hospital from February 2020 to May 2021

    by Fatemeh Hayati, Sahar GholizadehTahamtan, Maryam Khombi Shooshtari, Ali Ghorbani, Leila Sabetnia, Eisa Rezaei, Seyed Seifollah Beladi Mousavi

    Background: End-stage renal disease patients on maintenance hemodialysis (ESRD-HD) are at very high risk for COVID-19 infections due to their older age and comorbidities such as diabetes and hypertension. Objectives: This study aimed to investigate the outcomes of COVID-19 in ESRD-HD patients. Methods: This was a retrospective study conducted on ESRD-HD patients aged 18 years and older who were referred to Razi Hospitals in Ahvaz from February 2020 to May 2021 for hemodialysis and diagnosed with COVID-19. Patient information was extracted retrospectively from their medical records. Results: A total of 180 patients were examined. The average age of the patients was 61.5 years, and 118 (65.6%) were men. The most common underlying condition was hypertension (81.1%). The most prevalent clinical symptom was shortness of breath (70.6%), followed by cough (47.8%). Seventy-five patients (41.66%) were admitted to the intensive care unit (ICU), with an average stay of 5 days. Hypertension and ischemic heart disease were significantly more common among patients admitted to the ICU (P = 0.008 and 0.015, respectively). In-hospital mortality was 32.8%. Advanced age, fever, shortness of breath, cough, and the need for a ventilator were significant predictors of mortality in hospitalized ESRD patients with COVID-19 (P = 0.016, 0.033, 0.001, 0.012, and 0.011, respectively). Conclusions: Our study demonstrated that ESRD-HD patients with COVID-19 are at high risk for ICU admission and mortality. Advanced age and clinical symptoms such as fever, shortness of breath, cough, and the need for a ventilator significantly predict in-hospital mortality in these patients.


  • Open Access

    The impact of intra-sacroiliac joint methylprednisolone injection in the recovery of patients with spondyloarthropathy: a randomized controlled trial

    by Elham Rajaei, Khaled Bavieh, Karim Mowla, Ali Ghorbani, Nooshin Movaffagh

    Introduction Spondyloarthropathies are a group of chronic inflammatory diseases with specific clinical symptoms in rheumatic diseases. These patients suffer from pain in the joints. Physicians have tried several ways to decrease the pain in these patients. This study aimed to evaluate the...


  • Open Access

    Evaluation of mortality of COVID-19 patients with acute kidney injury (AKI) in comparison to the non-AKI patients

    by Heshmatollah Shahbazian, Mina Tafazoli, Leila Sabet Nia, Ali Ghorbani, Shahla Ahmadi Halili, Fatemeh Jahangiri Mehr

    Introduction: Acute kidney injury (AKI) is prevalent in the coronavirus disease-2019 (COVID-19). There are little data on the relationship between renal dysfunction and COVID-19 prognosis. Objectives: The aim of this research was to investigate the effects of AKI in COVID-19 patients hospitalized to the Golestan and Razi hospitals in Ahvaz, Iran. Patients and Methods: In this retrospective cohort study, a total of 194 COVID-19 patients were included, consisting of 79 patients with AKI and 115 patients without AKI. Primary and secondary outcomes were compared between the two groups. Results: According to the findings, mortality was significantly different between the two groups, and mortality was higher in the AKI group (P< 0.001). The mean length of hospital stay was statistically significantly higher in the AKI group (P=0.024). Moreover, there was a significant correlation between intensive care unit (ICU) admission and the study group (P<0.001). Staging of AKI group were seen as; stage I (49.37%), stage II (36.71%), and stage III (13.92%). No significant correlation was observed between outcome and the stages of AKI (P=0.496). Furthermore, 14 patients (17.72%) needed renal replacement therapy (RRT) in the AKI group. Conclusion: Although AKI is a common finding in COVID-19 patients, most patients were in stage I disease, which returned to normal after COVID-19 treatment. According to our research, COVID-19 rarely leads to serious and persistent kidney injury. However, the risk of death is increased in COVID-19 patients with AKI. Therefore, it is necessary to evaluate the renal function tests during the course of disease.

  • Open Access

    Clinical manifestations and laboratory findings and mortality rate of kidney transplant recipients infected with COVID-19

    by Shokouh Shayanpour, Maryam Sadat Mavalizadeh, Leila Sabetnia, Heshmatolah Shahbazian, Ali Ghorbani, Zahra Mehraban

    Introduction: The emergence of a novel coronavirus (COVID-19) in late December 2019 and its rapid global spread has led World Health Organization (WHO) to introduce it as a very dangerous pandemic. People with underlying disease and a history of organ transplantation are at higher risk for COVID-19 disease compared with healthy people. Objectives: In the present study, clinical and laboratory manifestations in the patients with COVID-19 with a history of kidney transplantation has been investigated. Patients and Methods: This study conducted on 103 COVID-19-positive kidney transplant patients as a descriptive epidemiological study. Clinical and laboratory symptoms of hospitalized renal transplanted patients have been assessed. Statistical analysis of the collected data conducted using SPSS (Statistical Package for Social Sciences, version 22). Results: This study consisted of 103 COVID-19 patients with a history of kidney transplant, of which 64 males (62.1%) and 39 females (37.9%) with an average age of 48.5 ± 13.1 years. The most common clinical manifestations were headache (67%) and shortness of breath (66%). Elevated lactate dehydrogenase (LDH) levels, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) has been observed in 100%, 98.1% and 93.2% of patients, respectively. In 12.6% and 41.7% of patients, the degree of lung involvement was above 75% and 50%-75%, respectively. Moreover, 79.6% of patients has been discharged after improved, while 20.4% of patients died. Conclusion: We found, kidney transplantation may increase COVID-19-related mortality when compared to COVID-19-related mortality in the general population.

  • Open Access

    The effect of single dose prophylactic vancomycin before semi-permanent catheterization to prevent catheter related infection; a randomized controlled trial, phase II

    by Asieh Aref, Zohreh Zandbaf, Ali Ghorbani, Shahla Ahmadi Halili

    Introduction: Catheter-related infections are a common complication and a major cause of morbidity and mortality in hemodialysis patients with tunneled central venous catheters. The optimal strategy for the management and prevention of catheter-related infections is unclear. Objectives: This study is aimed to evaluate the single-dose prophylactic vancomycin efficacy before semi-permanent catheterization to prevent catheter-related infection. Patients and Methods: This randomized double-blind controlled clinical trial was conducted on patients with chronic renal failure requiring hemodialysis and insertion of a double-lumen central venous catheter admitted to Ahvaz Golestan Hospital. The intervention group (n=30) received 1 g of vancomycin intravenously one hour before catheter insertion and the control group (n=30) received an equal amount of normal saline. The incidence of catheter-related infections and other complications for 6 months was evaluated. Results: During the 6-month follow-up, hospitalization due to catheter-related infection and the need for antibiotic administration was observed in 9 patients (30.0%) who received vancomycin and 14 patients (46.7%) in the control group (P=0.184). Catheter extraction due to infection was observed in 4 patients of the vancomycin group (13.3%) and 6 patients of the control group (20.7%) (P=0.451). Complications other than infection were observed in four patients (13.3%) in each group (P=1.000). The mean time to onset of infection was 2.43 ±0.38 months in the control group and 3.85 ± 0.42 months in the vancomycin group (P=0.002). Conclusion: Although a single dose of intravenous vancomycin one hour before insertion of a bi-luminal hemodialysis catheter did not show a significant effect on preventing catheter-related infections over 6 months, it significantly delayed the onset of infection. Trial Registration: The trial protocol was approved by Iranian Registry of Clinical Trial (Ethical code: IR.AJUMS.HGOLESTAN.REC.1399.106 and IRCT code: IRCT20201206049617N1; https://www.irct.ir/trial/52832).


  • Open Access

    Effect of vitamin D treatment on magnesium levels in chronic hemodialysis patient; a double blind controlled clinical trial

    by Shahla Ahmadi Halili, Ali Ghorbani, Ebrahim Hamreh, Leila Sabetnia, Fatemeh Hayati, Khojasteh Hoseinynejad

    Introduction: The homeostasis of magnesium (Mg) is impaired in chronic kidney disease (CKD) and it has been suggested that intestinal absorption of Mg may be affected by vitamin D status. 25-Hydroxy vitamin D or 25(OH)D deficiency is common in patients undergoing chronic hemodialysis; however the efficacy of nutritional vitamin D supplementation on Mg level in this population remains uncertain. Objectives: The aim of this study was to evaluate the effect of vitamin D treatment on Mg levels in chronic hemodialysis patients. Patients and Methods: This randomized clinical trial study was conducted on 69 chronic hemodialysis patients (mean age of 56.93 ±12.26 years) with serum 25-hydroxy vitamin D levels <30 ng/mL. The patients were randomly assigned to one of treatment groups of oral vitamin D3- 50 000 units per week (n=35; experimental group) or 500 mg calcium D3 tablets, every 12 hours (n=34; control group) for three months. At the beginning and end of the treatment period, the levels of serum 25-hydroxy vitamin D and the levels of Mg, calcium, phosphorus and intact parathyroid hormone (iPTH) were measured in two groups. Results: In both groups, serum vitamin D levels increased significantly after treatment (P<0.0001 for both groups), however after three months of treatment, in the experimental group the levels of vitamin D were significantly higher than the patients in the control group (57 ng/mL versus 28 ng/mL; P<0.0001) and the median increase of vitamin D after treatment in the experimental group was significantly higher than the control group (40 ng/mL versus 10.5; P0.05). Conclusion: Our study shows that oral vitamin D therapy can increase 25(OH)D levels in maintenance hemodialysis patients without significant alterations in serum calcium, phosphate, magnesium and parathyroid hormone during a 12-week period. Trial Registration: Registration of trial protocol has been approved by the Iranian registry of clinical trial (#IRCT20210314050698N1; https://en.irct.ir/trial/55159, local ethical code# IR.SKUMS.REC.1397.181).

  • Open Access

    Effect of rituximab on reducing the panel-reactive antibody in dialysis patients of transplant candidate

    by Asieh Aref, Samaneh Tirom, Heshmatollah Shahbazian, Ali Ghorbani

    Introduction: Based on the evidence, rituximab may be an effective treatment for kidney transplantation for reducing panel-reactive antibody. Objectives: This study was conducted to investigate the effect of rituximab on reducing the panel in transplant dialysis patients. Patients and Methods: This is an interventional study that was conducted on 20 dialysis patients who were candidates for kidney transplantation. Patients first had a panel-reactive antibody test and patients with a panel-reactive antibody above the age of 30 were included in the study. First, rituximab was administered at a dose of one gram and then after two weeks, another dose of one gram was administered. Panel-reactive antibody was measured baseline, one and six months later. Results: One and six months after stopping the drug, we found a significant decrease in the mean amount of reactive antibodies. Additionally, six months after stopping the drug, a significant decrease in the level of patients’ reactive antibodies in comparison to one month before taking the drug was detected (P<0.05). Conclusion: The findings showed that treatment with rituximab is useful for reducing panel-reactive antibody in kidney transplant patients. However, more studies are needed to optimize rituximab injection protocols.

  • Open Access

    Musculoskeletal manifestation of kidney transplant recipients

    by Karim Mowla, Hajieh Shahbazian, Asghar Sharif Najafi, Ali Ghorbani

    Introduction: Kidney transplantation has been established as an effective treatment method for patients with end-stage renal disease. Objectives: The purpose of this study was to determine the prevalence of musculoskeletal complaints following kidney transplant. Patient and Methods: We designed a retrospective-descriptive study on kidney transplant recipients. This study was performed on medical records of 1189 kidney transplant patients referring to the kidney transplantation ward of Golestan hospital (Ahvaz, Iran). Results: The mean age of the participants was 42.8 ± 13.5 years. Out of the 1189 patients, 231 (22.3%) had musculoskeletal manifestations, with the most prevalent problem being non-inflammatory pain (41.4%). Additionally, degenerative joint disease, especially in the lumbar spine, was the most common clinical finding in this study (24%). Besides, hypovitaminose D (71.4%) and elevated parathyroid hormone levels (51.3%) and hyperuricemia (50.8%) were the most common laboratory abnormalities observed in our patients. Conclusion: Approximately 22.3% of our renal transplant patients had musculoskeletal manifestations. Attention to earlier detection of these manifestations through regular examinations would reduce the complications and burden of the disease.

  • Open Access

    The prevalence of malnutrition in hemodialysis patients

    by Ali Ghorbani, Fatemeh Hayati, Majid Karandish, Soudabeh Sabzali

    Introduction: Malnutrition is a complex, multi-factorial and common problem in patients with end-stage renal disease (ESRD) undergoing hemodialysis that increases morbidity and mortality rate in them. Objectives: To assess the prevalence of malnutrition and associated factors in hemodialysis patients. Patients and Methods: This cross-sectional study was conducted on 239 hemodialysis patients (162 males and 77 females) referred to three dialysis centers in Ahvaz, Iran in 2018. The nutritional statuswas measured using subjective global assessment (SGA)tool. The anthropometric indices, body mass index (BMI) and biochemical parameters including albumin, triglyceride, C-reactive protein (CRP), and adequacy of dialysis (Kt/V) were also measured in all patients. Results: Based on SGA, 45 (18.8%) patients including 32 males and 13 females had mild to moderate malnutrition while 26 (10.9%) patients consisting of 11 men and 15 women had severe malnutrition. We found a significant association between patients’ gender and malnutrition status (P=0.013). In addition, a significant association was seen between age (P=0.024), BMI (P=0.0001), CRP (P=0.047) and serum albumin concentration (P=0.007) with nutritional status. However, we did not find any significant association between triglyceride, Kt/V and duration of hemodialysis per week with malnutrition (P>0.05). Moreover, BMI, patient’s gender and serum albumin were the significant predictors of severe malnutrition in hemodialysis patients (PConclusion: According to high prevalence of malnutrition in ESRD patients undergoing hemodialysis, periodic assessment of nutritional status is necessary for them. Moreover, female patients, CRP, serum albumin and BMI showed a significant correlation with SGA score, which are important to determine the nutritional status of hemodialysis patients (HD) patients.


  • Open Access

    Taurolock versus saline 5% on preventing infection and dysfunction of hemodialysis catheters; a randomized, double blind controlled clinical trial

    by Ali Ghorbani, Fatemeh Hayati, Mehrdad Dargahi-MalAmir, Maryam Afkane

    Introduction: Despite the higher rate of morbidity and mortality, the use of central venous catheters has increased significantly compared to arteriovenous fistula. So far, no ideal organic solution has been identified for the prevention of thrombosis and catheter-related infection in patients undergoing hemodialysis. Objectives: This study aimed to evaluate the efficacy of Taurolock versus saline 5% on the prevention of catheter dysfunction and catheter-related infections. Patients and Methods: Seventy patients with chronic kidney disease, who requiring hemodialysis or those with permanent hemodialysis catheters referring to hemodialysis centers of Ahvaz, were selected and randomly divided into two groups, while 68 patients remained until the end of the study. In the first group, saline 5% was inserted into the lumen of catheter after each hemodialysis, and then catheter was blocked. In the second group, Taurolock solution (TauroLock™ -Hep 500®: Taurolidine; antimicrobial agent), citrate 4% and heparin (UI/mL) were used as antibiotics. Results: No significant difference between the catheter-related infection and positive blood culture in both saline and Taurolock groups was detected (2.94% versus 2.94%; P >0.05). Moreover, the catheter-related dysfunction in the saline 5% group was 5% less than the Taurolock group (2.94% versus 11.76%, P = 0.365). Conclusion: The results showed that saline 5% is at least as effective as a Taurolock solution for prevention of infections and catheter dysfunction. Saline is an effective, inexpensive, safe and readily available in various settings. Therefore, it could be considered as a proper alternative solution for reduction of dialysis-related side effects and costs. Trial Registration: Registration of trial protocol has been approved in Iranian registry of controlled trials (identifier: IRCT20190304042918N1; https://en.irct.ir/trial/38055, ethical code# IR.AJUMS.REC.1397.412).